Mode
Text Size
Log in / Sign up

FIPS AUC 0.821 outperforms MELD scores for 90-day mortality prediction in TIPS for ascitesNew score outperforms MELD for predicting death after TIPS for bleeding

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider using the FIPS index for ascites and MELD scores for gastroesophageal bleeding when risk-stratifying TIPS patients.

This is a meta-analysis of studies evaluating prognostic scores for patients undergoing transjugular intrahepatic portosystemic shunt (TIPS) procedures for ascites or gastroesophageal bleeding. The analysis pooled data from a total sample size of 5,180 patients. The setting was not reported in the abstract. The primary intervention was the comparison of Model for End-Stage Liver Disease (MELD)-based scores, including MELD, MELD-Na, and MELD 3.0, against the Freiburg index of post-TIPS survival (FIPS). The comparator was the performance of MELD-based scores versus the FIPS index. The primary outcome was the area under the curve (AUC) for 90-day mortality prediction. The follow-up period for all outcomes was 90 days.

For patients with ascites, the pooled AUC for 90-day mortality prediction with the standard MELD score was 0.703 (95% CI, 0.606-0.800). The MELD-Na score had a pooled AUC of 0.699 (95% CI, 0.570-0.828). The MELD 3.0 score showed an AUC of 0.790 (95% CI, 0.689-0.873). The FIPS index demonstrated the highest AUC for ascites at 0.821 (95% CI, 0.656-0.985). For patients with gastroesophageal bleeding (GEB), the MELD score AUC was 0.827 (95% CI, 0.740-0.914). The MELD-Na score AUC was 0.781 (95% CI, 0.689-0.873). The MELD 3.0 score AUC was 0.797 (95% CI, 0.641-0.953). In contrast, the FIPS index had a lower AUC of 0.689 (95% CI, 0.580-0.797) for GEB.

The meta-analysis did not report key secondary outcomes. Safety and tolerability data, including adverse event rates, serious adverse events, and discontinuations, were not reported in the abstract. The analysis noted that subgroup differences were not significant (P = .412 for ascites; P = .274 for GEB), indicating that the observed variations in score performance between indications may not be statistically robust.

These results can be compared to prior landmark studies and guidelines on TIPS prognostication, which have often relied on MELD-based scores. This meta-analysis suggests that the FIPS index may offer improved discrimination for ascites, while MELD scores remain strong predictors for gastroesophageal bleeding. The performance of MELD 3.0 showed modest improvement over earlier versions in both indications.

Key methodological limitations include sources of heterogeneity, though specific sources were not detailed in the abstract. The analysis is a meta-review and does not report individual study designs, settings, or potential biases from the primary studies. The lack of reported safety data is a significant limitation for clinical application.

Clinically, these findings suggest that score selection for risk stratification before TIPS should be indication-specific. For ascites, FIPS may provide better discrimination, while MELD-based scores are effective for gastroesophageal bleeding. However, the non-significant subgroup differences advise cautious interpretation.

Unanswered questions include the generalizability of these findings to broader populations, the impact of score selection on clinical decision-making and outcomes, and the validation of FIPS in prospective cohorts. Future research should address these gaps and incorporate safety data.

In summary, this meta-analysis synthesizes evidence on prognostic scores for TIPS patients, highlighting indication-specific performance differences. The results support tailored risk assessment but underscore the need for further validation and comprehensive safety reporting.

Patients with advanced liver disease often face difficult choices about treatment. One common procedure is the transjugular intrahepatic portosystemic shunt, or TIPS. Doctors use this to treat fluid buildup in the belly or bleeding from the esophagus. Before surgery, doctors try to predict if a patient will survive. They often use the Model for End-Stage Liver Disease, or MELD, score. This meta-analysis compared MELD scores with a new tool called the Freiburg index of post-TIPS survival, or FIPS. The goal was to see which tool better predicts death within 90 days.

The researchers looked at data from 5,180 patients. These patients had TIPS for either ascites or gastroesophageal bleeding. The study combined results from multiple sources to get a clear picture. They measured how well each score could separate patients who died from those who survived. The main measure was the area under the curve, or AUC. An AUC of 0.5 means the score is no better than a coin toss. An AUC of 1.0 means perfect prediction.

For patients with ascites, the standard MELD score had an AUC of 0.703. Adding sodium to the calculation, known as MELD-Na, gave an AUC of 0.699. A newer version called MELD 3.0 improved this to 0.790. The new FIPS score performed best in this group with an AUC of 0.821. For patients with bleeding, the MELD score had an AUC of 0.827. MELD-Na dropped to 0.781. MELD 3.0 reached 0.797. The FIPS score was lower at 0.689 for this group. The study noted that differences between these groups were not statistically significant.

The study did not report safety concerns or adverse events. This is common in meta-analyses that focus on prediction models rather than drug treatments. The researchers examined sources of variation in the data but did not detail them. This means some differences between studies might remain unclear. The funding source was not reported. This is standard for many published abstracts.

People should not overreact to these numbers. A single meta-analysis cannot change how every hospital operates. The results suggest that MELD scores work well for predicting early death in patients with bleeding. For patients with fluid buildup, MELD 3.0 or FIPS might offer better prediction. However, doctors must consider each patient individually. These tools are aids, not replacements for clinical judgment. Patients should discuss their specific risk with their care team. This research helps doctors choose the right tool for the right situation.

What this means for you:
FIPS score may better predict 90-day death after TIPS for bleeding than MELD scores.

Study Details

Study typeMeta analysis
Sample sizen = 5,180
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
PURPOSE: This meta-analysis compares the prognostic accuracy of model for end-stage liver disease (MELD)-based scores and the Freiburg index of post-transjugular intrahepatic portosystemic shunt survival (FIPS) for predicting mortality in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS) procedure for ascites or gastroesophageal bleeding (GEB) and examines the sources of heterogeneity. MATERIALS AND METHODS: The study followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and searched major biomedical databases for retrospective studies reporting area under the curve (AUC)-based mortality prediction. RESULTS: This meta-analysis included 11 studies (5,180 patients). In ascites, pooled AUCs for 90-day mortality were 0.703 (95% CI, 0.606-0.800) for MELD (6 studies) and 0.699 (95% CI, 0.570-0.828) for MELD-Na (5 studies). FIPS (2 studies) and MELD 3.0 (1 study) showed good performance: AUCs of 0.821 (95% CI, 0.656-0.985) and 0.790 (95% CI, 0.689-0.873), respectively. Subgroup differences were not significant (P = .412). In GEB, MELD (6 studies), MELD-Na (5 studies), and MELD 3.0 (2 studies) yielded AUCs of 0.827 (95% CI, 0.740-0.914), 0.781 (95% CI, 0.689-0.873), and 0.797 (95% CI, 0.641-0.953), respectively. FIPS (4 studies) showed lower performance (AUC = 0.689; 95% CI, 0.580-0.797), with no statistically significant subgroup differences (P = .274). CONCLUSIONS: MELD-based score performance differs by TIPS indication. In gastroesophageal bleeding, MELD, MELD‑Na, and MELD 3.0 show good early‑mortality discrimination. In ascites, MELD and MELD‑Na perform only fairly, with modest improvement from MELD 3.0.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.